These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2841390)

  • 1. [Clinical experiences in tumor-oriented anti-cancer drugs].
    Ohsawa N
    Nihon Naika Gakkai Zasshi; 1988 Mar; 77(3):313-7. PubMed ID: 2841390
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bestrabacil: a possible target-oriented anticancer agent].
    Ohsawa N; Yamazaki Z; Wagatsuma T; Isurugi K
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2115-24. PubMed ID: 6548354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednimustine for prostate cancer therapy.
    Slack NH; Murphy GP
    Compr Ther; 1979 Sep; 5(9):54-7. PubMed ID: 487742
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical effects of bestrabucil (KM2210) in bladder cancer].
    Nasu Y; Saegusa M; Ochi J; Hara M; Akagi T; Obama T; Yoshimoto J; Matsumura Y; Ohmori H; Tsushima T
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3155-6. PubMed ID: 3674900
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tumor-oriented anti-cancer agent with estrogen as a carrier].
    Ohsawa N; Yamazaki Z
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1065-71. PubMed ID: 3291767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I study of bestrabucil (KM 2210)].
    Kamei H; Takenaka K; Goto T; Suga S; Fugiwara A; Nakao I; Agatsuma T; Fujita K; Isurugi K; Kubota T
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2208-15. PubMed ID: 3755019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early phase II trial of bestrabucil in hematological malignancies].
    Nagura E; Ohno R; Yamada K; Akao Y; Naito K; Nishikawa M; Tanaka H; Shirakawa S; Ono Y; Ezaki K
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2216-22. PubMed ID: 3459398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
    Mittelman A; Catane R; Murphy GP
    Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new anti-cancer agent, bestrabucil (KM 2210): I. Concentration in the serum and tissue in urogenital tumors].
    Nasu Y; Saegusa M; Hara M; Ochi J; Akagi T; Obama T; Tsushima T; Yoshimoto J; Ozaki Y; Matsumura Y
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1116-21. PubMed ID: 3566306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednimustine: the rationale for clinical development.
    Schein PS; Cavalli F
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):1-2. PubMed ID: 3952515
    [No Abstract]   [Full Text] [Related]  

  • 11. Prednimustine.
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):1-44. PubMed ID: 3952516
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
    Ueda T; Sakai K; Morimoto K; Nakatani S
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3285-9. PubMed ID: 3688892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III study of prednimustine (LEO 1031) in advanced breast cancer. A preliminary report.
    Rørth M; Løber J; Dombernowsky P; Krusenstjerna-Hofstrom D; Mattsson W; Mouridsen HT
    Eur J Cancer (1965); 1980; Suppl 1():137-40. PubMed ID: 7032923
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
    Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
    J Urol; 1979 Jun; 121(6):763-5. PubMed ID: 458947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antitumor effect of prednimustine in vitro and in vivo.
    Hartley-Asp B
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):3-7. PubMed ID: 3952519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration.
    Loos U; Musch E; Malek M; Riedel E
    Oncology; 1991; 48(4):334-42. PubMed ID: 1891177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Targeting therapy of cancer, using hormones as carriers].
    Ohsawa N
    Nihon Rinsho; 1989 Jun; 47(6):1417-22. PubMed ID: 2770003
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II trial of prednimustine in children with recurrent cancer: a Children's Cancer Study Group report.
    Gaynon PS; Baum ES; Krivit W; Hammond D
    Cancer Treat Rep; 1982 Jul; 66(7):1583-4. PubMed ID: 6284362
    [No Abstract]   [Full Text] [Related]  

  • 19. [Quantitative assay of growth response of clinical breast cancer cells against E2 or E2-conjugated drugs].
    Matsuoka H; Furusawa M; Sugimachi K
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1705-6. PubMed ID: 8060151
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experience with estramustine phosphate and predinimustine, two steroidal alkylating agents compounds [proceedings].
    Catane R
    Cancer Treat Rep; 1978 Aug; 62(8):1264-5. PubMed ID: 688269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.